What is Sofosbuvir + Daclatasvir?

Sofosbuvir + Daclatasvir is a highly effective, direct-acting antiviral (DAA) combination therapy used for the treatment of chronic Hepatitis C virus (HCV) infection. This pan-genotypic regimen combines two distinct viral inhibitors that directly target and disrupt the replication cycle of the Hepatitis C virus.

By targeting different non-structural proteins essential for viral replication, this combination achieves extremely high cure rates—defined as Sustained Virologic Response (SVR12)—across multiple HCV genotypes with a short duration of oral therapy.

What is Sofosbuvir + Daclatasvir Used For?

This combination regimen is prescribed for adult patients (and eligible pediatric populations meeting specific guidelines) for the treatment of chronic Hepatitis C virus (HCV) infection:

• Pan-Genotypic Coverage: Effective against HCV Genotypes 1, 2, 3, 4, 5, and 6.
• Broad Patient Spectrum: Indicated for patients without cirrhosis (non-cirrhotic) as well as those with compensated cirrhosis.
• Special Populations: Commonly utilized in patients co-infected with HIV-1, as well as those with post-transplant HCV recurrence, under expert specialist supervision.

How Does Sofosbuvir + Daclatasvir Work?

The two active pharmaceutical ingredients act synergistically at separate molecular targets within the HCV replication complex:

• Sofosbuvir (NS5B Polymerase Inhibitor): Sofosbuvir is a nucleotide analog prodrug that is intracellularly metabolized into its active triphosphate form. It incorporates into viral RNA via the HCV NS5B RNA-dependent RNA polymerase, causing immediate RNA chain termination and halting viral replication.
• Daclatasvir (NS5A Inhibitor): Daclatasvir binds directly to the NS5A non-structural protein, a key domain required for both viral RNA replication and the assembly of new HCV virions.
• Synergistic Viral Clearance: By simultaneously blocking NS5B and NS5A, the combination rapidly drops HCV RNA viral loads to undetectable levels and prevents viral resistance from developing.

Benefits of Sofosbuvir + Daclatasvir

• Pan-Genotypic Potency: Delivers cure rates exceeding 95% across major HCV genotypes without requiring interferon injections.
• Interferon-Free & Ribavirin-Sparing: Eliminates the severe systemic side effects historically associated with pegylated interferon regimens (in many patients, ribavirin is also unnecessary).
• Once-Daily Oral Therapy: Delivered as simple daily oral administration over a standard 12-week or 24-week treatment course.

Available Strengths

Sofosbuvir and Daclatasvir are administered either as separate single-agent co-packaged tablets or as a single fixed-dose combination (FDC) tablet:

• Fixed-Dose Combination Tablet:

o Sofosbuvir 400 mg / Daclatasvir 60 mg film-coated tablets

• Individual Monotherapy Formulations:

o Sofosbuvir: 400 mg film-coated tablets
o Daclatasvir: 60 mg (also available in 30 mg for dose adjustments with specific interacting drugs) film-coated tablets

Recommended Dosage & Administration

Dosing duration depends on HCV genotype, presence of cirrhosis, and prior treatment history.

Standard Adult Dosage Guidelines

• Standard Regimen: One Sofosbuvir 400 mg / Daclatasvir 60 mg combination (or individual tablets taken together) orally once daily.

• Standard Treatment Duration:

o Non-cirrhotic or Compensated Cirrhosis (Genotypes 1, 2, 4, 5, 6): 12 weeks.
o Genotype 3 or Decompensated Cirrhosis: 12 to 24 weeks (sometimes co-administered with low-dose Ribavirin based on clinical guidelines).

Administration Rules

• With or Without Food: Can be taken with or without food.
• Swallow Whole: Swallow tablets whole with water. Do not chew, split, or crush the tablets.
• Consistency is Key: Take your daily dose at approximately the same time every day to maintain steady antiviral drug levels.

Missed Dose

• If a dose is missed within 18 hours of the scheduled time, take it immediately and take the next dose at the regular time. If more than 18 hours have passed, skip the missed dose and resume your regular schedule. Do not take two doses at once.

Common & Serious Side Effects

Sofosbuvir + Daclatasvir is generally well-tolerated with a favorable safety profile compared to older HCV therapies:

• Common Mild Effects: Headache, fatigue/unusual tiredness, nausea, insomnia, and mild diarrhea.
• Hepatitis B Reactivation (Boxed Warning): Risk of severe acute flare-up or reactivation of Hepatitis B virus (HBV) in patients co-infected with HBV and HCV. All patients must be screened for HBV prior to initiating treatment.
• Severe Symptomatic Bradycardia: Taking Sofosbuvir in combination with amiodarone can cause life-threatening slowing of the heart rate (bradycardia), requiring cardiac monitoring or alternative treatment choices.
• Anemia (if combined with Ribavirin): Hemoglobin reduction requiring routine blood count monitoring when Ribavirin is added to the regimen.

Drug Interactions

Daclatasvir is a substrate of CYP3A4, and both agents are substrates of P-glycoprotein (P-gp):

• Strong CYP3A4 / P-gp Inducers: Drugs such as rifampin, carbamazepine, St. John’s Wort, oxcarbazepine, and phenytoin significantly reduce blood concentrations of Sofosbuvir and Daclatasvir, leading to loss of therapeutic response and potential viral resistance. Co-administration is contraindicated.
• Strong CYP3A4 Inhibitors: Protease inhibitors or certain azole antifungals can increase Daclatasvir concentrations; a dose reduction of Daclatasvir to 30 mg once daily may be required.
• Moderate CYP3A4 Inducers: Certain HIV medications (e.g., efavirenz, etravirine, nevirapine) decrease Daclatasvir levels, requiring an increased Daclatasvir dose of 90 mg once daily.
• Amiodarone: Concomitant use with Sofosbuvir is strongly disadvised due to risks of severe cardiac dysfunction.

Pregnancy and Breastfeeding

• Sofosbuvir + Daclatasvir Alone: Clinical data in pregnant women are limited. Treatment should generally be deferred until after delivery unless immediate therapy is medically required.
• Regimens with Ribavirin: If Ribavirin is added, it causes severe birth defects and embryo-fetal lethality. Strict double contraception is required for female patients and male partners during treatment and for 6 months post-treatment.
• Breastfeeding: It is unknown whether Sofosbuvir or Daclatasvir passes into human breast milk. Mothers should consult their physician to weigh the clinical need against infant risk.

Monitoring During Treatment

To ensure complete viral elimination and patient safety, healthcare teams perform regular monitoring:

• HBV Screening: Baseline testing for HBsAg and anti-HBc prior to treatment initiation.
• HCV RNA Quantification: Serum HCV RNA tests at baseline, week 4 (optional), end of treatment, and 12 weeks post-treatment to confirm Sustained Virologic Response (SVR12 = cure).
• Liver Function Tests (LFTs): Baseline and periodic monitoring of serum transaminases and bilirubin.
• Renal Function: Monitoring serum creatinine and eGFR, particularly in patients with pre-existing renal impairment.

Generic Sofosbuvir + Daclatasvir

Generic formulations of Sofosbuvir and Daclatasvir are produced globally under stringent international regulatory standards:

• Cost-Effectiveness: Provides a highly affordable, accessible alternative compared to legacy brand-name combinations (e.g., Sovaldi + Daklinza).
• Therapeutic Equivalence: Contains the exact active pharmaceutical ingredients (APIs), maintaining bioequivalent viral suppression rates, safety profiles, and cure outcomes.
• Global HCV Elimination: Plays a pivotal role in public health programs aiming to eradicate Hepatitis C worldwide.

Frequently Asked Questions (FAQs)

What does "cured" mean in Hepatitis C treatment?

A patient is considered cured when HCV RNA remains undetectable in the blood 12 weeks after completing the full treatment course (known as Sustained Virologic Response, or SVR12).

Can I stop taking the medication early if my viral load drops to zero?

No. Even if the Hepatitis C virus becomes undetectable in blood tests within a few weeks, you must complete the full prescribed duration (12 or 24 weeks) to prevent remaining latent viral particles from causing a relapse.

Can I get infected with Hepatitis C again after being cured?

Yes. Successful treatment with Sofosbuvir + Daclatasvir clears the current infection but does not create permanent immunity. Re-exposure to the Hepatitis C virus can cause a new infection.

Important Safety Information

This article is intended for educational purposes only and does not substitute for expert medical advice. Always consult a qualified hepatologist, gastroenterologist, or infectious disease specialist before initiating, adjusting, or stopping Hepatitis C therapy.

References

• World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Infection
• European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C
• American Association for the Study of Liver Diseases (AASLD) / Infectious Diseases Society of America (IDSA) HCV Guidance

Contact Us

Are you searching for Generic Sofosbuvir + Daclatasvir, wholesale pricing structures, global availability, or export documentation?

Our expert team is fully equipped to guide you through trusted manufacturer selections, product availability, international licensing, and country-specific import regulations. Contact us today to learn more.

• Sofosbuvir + Daclatasvir